Eli Lilly wins FDA approval of donanemab for Alzheimer’s (NYSE:LLY)
2024-07-02
jetcityimage/iStock Editorial via Getty Images The U.S. FDA has approved Eli Lilly’s (NYSE:LLY) donanemab as a treatment for early Alzheimer’s disease. The therapy, which is given via infusion once a month, will be marketed under the name Kisunla. Lilly noted that the treatment will cost $12,522 over six months andContinue Reading